KR20120002129A - 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체 - Google Patents

면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체 Download PDF

Info

Publication number
KR20120002129A
KR20120002129A KR1020100062860A KR20100062860A KR20120002129A KR 20120002129 A KR20120002129 A KR 20120002129A KR 1020100062860 A KR1020100062860 A KR 1020100062860A KR 20100062860 A KR20100062860 A KR 20100062860A KR 20120002129 A KR20120002129 A KR 20120002129A
Authority
KR
South Korea
Prior art keywords
immunoglobulin
facviia
region
conjugate
facvii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020100062860A
Other languages
English (en)
Korean (ko)
Inventor
송대해
임성인
김창환
홍성갑
임대성
권세창
Original Assignee
한미홀딩스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미홀딩스 주식회사 filed Critical 한미홀딩스 주식회사
Priority to KR1020100062860A priority Critical patent/KR20120002129A/ko
Priority to ARP110102301A priority patent/AR082032A1/es
Priority to PCT/KR2011/004796 priority patent/WO2012002745A2/en
Priority to EP11801151.9A priority patent/EP2588142A2/en
Priority to JP2013518254A priority patent/JP2013533875A/ja
Priority to CN2011800325807A priority patent/CN103025358A/zh
Priority to TW100123053A priority patent/TWI443106B/zh
Priority to US13/807,572 priority patent/US20130095090A1/en
Publication of KR20120002129A publication Critical patent/KR20120002129A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
KR1020100062860A 2010-06-30 2010-06-30 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체 Ceased KR20120002129A (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020100062860A KR20120002129A (ko) 2010-06-30 2010-06-30 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체
ARP110102301A AR082032A1 (es) 2010-06-30 2011-06-29 Complejo de factor viia en el que se utiliza un fragmento de inmunoglobulina
PCT/KR2011/004796 WO2012002745A2 (en) 2010-06-30 2011-06-30 Factor viia complex using an immunoglobulin fragment
EP11801151.9A EP2588142A2 (en) 2010-06-30 2011-06-30 Factor viia complex using an immunoglobulin fragment
JP2013518254A JP2013533875A (ja) 2010-06-30 2011-06-30 免疫グロブリン断片を用いた第７因子（ＦａｃｔｏｒＶＩＩａ）薬物結合体
CN2011800325807A CN103025358A (zh) 2010-06-30 2011-06-30 使用免疫球蛋白片段的因子viia复合物
TW100123053A TWI443106B (zh) 2010-06-30 2011-06-30 使用免疫球蛋白片段之ＶＩＩａ因子錯合物
US13/807,572 US20130095090A1 (en) 2010-06-30 2011-06-30 Factor viia complex using an immunoglobulin fragment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100062860A KR20120002129A (ko) 2010-06-30 2010-06-30 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체

Publications (1)

Publication Number Publication Date
KR20120002129A true KR20120002129A (ko) 2012-01-05

Family

ID=45402578

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100062860A Ceased KR20120002129A (ko) 2010-06-30 2010-06-30 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체

Country Status (8)

Country Link
US (1) US20130095090A1 (https=)
EP (1) EP2588142A2 (https=)
JP (1) JP2013533875A (https=)
KR (1) KR20120002129A (https=)
CN (1) CN103025358A (https=)
AR (1) AR082032A1 (https=)
TW (1) TWI443106B (https=)
WO (1) WO2012002745A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101892687B1 (ko) 2017-05-18 2018-08-28 세종대학교산학협력단 하이드라진 연료전지용 전극과 이를 포함하는 막 전극 접합체 및 연료전지

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
WO2015154139A1 (en) * 2014-04-11 2015-10-15 Csl Limited Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor
BR112018014870A2 (pt) * 2016-01-21 2018-12-11 Protein Dynamic Solutions Llc método e sistema para análise de dados espectrais
CN111849945B (zh) * 2019-04-25 2024-11-29 正大天晴药业集团股份有限公司 人凝血因子VIIa的纯化方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2574581T3 (es) * 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
JP2007509843A (ja) * 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ＶＩＩ／ＶＩＩａ因子活性を有するハイブリッド分子
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
EP1937719A4 (en) * 2005-08-19 2010-11-24 Novo Nordisk As GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA
EP2089052A4 (en) * 2006-05-24 2011-02-16 Peg Biosciences POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS
WO2008025856A2 (en) * 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
UA101670C2 (ru) * 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101892687B1 (ko) 2017-05-18 2018-08-28 세종대학교산학협력단 하이드라진 연료전지용 전극과 이를 포함하는 막 전극 접합체 및 연료전지

Also Published As

Publication number Publication date
CN103025358A (zh) 2013-04-03
JP2013533875A (ja) 2013-08-29
US20130095090A1 (en) 2013-04-18
WO2012002745A3 (en) 2012-04-26
WO2012002745A2 (en) 2012-01-05
TW201217396A (en) 2012-05-01
AR082032A1 (es) 2012-11-07
TWI443106B (zh) 2014-07-01
EP2588142A2 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
US9364520B2 (en) Factor VIII conjugates
TWI388570B (zh) 包含具有三個官能端的非肽醯聚合物的多肽複合物
TWI423813B (zh) 使用免疫球蛋白片段之長效β干擾素製劑
RU2620072C2 (ru) ПРОИЗВОДНЫЕ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ VII И VIIa, КОНЪЮГАТЫ И КОМПЛЕКСЫ, СОДЕРЖАЩИЕ ИХ, И ИХ ПРИМЕНЕНИЕ
KR20080098216A (ko) 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
KR20110017420A (ko) 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
KR20170036646A (ko) 면역글로불린 단편의 특정 위치를 연결 부위로 이용한 단백질 결합체
JP6676551B2 (ja) 改変フォンウィルブランド因子
CN105229025B (zh) 位点特异性胰岛素缀合物
JP2017165753A (ja) 免疫グロブリン断片を用いたヒト卵胞刺激ホルモン持続性製剤
CN103930447A (zh) 用于制备生理活性多肽复合物的方法
KR20120002129A (ko) 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체
TW201546093A (zh) 保留免疫球蛋白質Ｆｃ片段對ＦｃＲｎ之結合親和力之免疫球蛋白質Ｆｃ接合物
KR20190013615A (ko) 이두로네이트 2-설파타제 결합체
HK1196565B (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
HK1196565A (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
HK1196373A (en) Method for preparing physiologically active polypeptide complex

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20100630

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140407

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20100630

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150824

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150824

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I